Clinical Trial Update: A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer [EARLY_Phase 1]

View source ↗

Summary

Early-phase (Phase 1) clinical trial assessing sequential NKG2D CAR-NK cell therapy as second-line chemotherapy for non-resectable pancreatic cancer; currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• NKG2D CAR-NK cell therapy (NKG2D CAR-NK cells)

Snippet

Sponsor: Zhejiang University | Conditions: Pancreatic Cancer Non-resectable | EARLY_Phase 1 | Status: RECRUITING